Lynozyfic: A New Hope in Blood Cancer Treatment
Understanding Multiple Myeloma Multiple myeloma is the second most prevalent form of blood cancer worldwide, affecting over 187,000 people annually. In the United States alone, it is projected that more than 36,000 individuals will be diagnosed with this disease in 2025. Characterized by the proliferation of abnormal plasma cells in the bone marrow, multiple myeloma disrupts the production of healthy blood cells, weakens the immune system, and can severely damage bones and organs. Despite advancements in cancer therapies, the disease remains incurable and difficult to manage in advanced stages.
